JP2023524274A5 - - Google Patents

Info

Publication number
JP2023524274A5
JP2023524274A5 JP2022566726A JP2022566726A JP2023524274A5 JP 2023524274 A5 JP2023524274 A5 JP 2023524274A5 JP 2022566726 A JP2022566726 A JP 2022566726A JP 2022566726 A JP2022566726 A JP 2022566726A JP 2023524274 A5 JP2023524274 A5 JP 2023524274A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
compound
sars
coronavirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022566726A
Other languages
English (en)
Japanese (ja)
Other versions
JP7805010B2 (ja
JP2023524274A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/029840 external-priority patent/WO2021222534A1/en
Publication of JP2023524274A publication Critical patent/JP2023524274A/ja
Publication of JP2023524274A5 publication Critical patent/JP2023524274A5/ja
Application granted granted Critical
Publication of JP7805010B2 publication Critical patent/JP7805010B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022566726A 2020-05-01 2021-04-29 コロナウイルス感染を予防および処置する化合物および方法 Active JP7805010B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063018690P 2020-05-01 2020-05-01
US63/018,690 2020-05-01
PCT/US2021/029840 WO2021222534A1 (en) 2020-05-01 2021-04-29 Compounds and methods for prevention and treatment of coronavirus infections

Publications (3)

Publication Number Publication Date
JP2023524274A JP2023524274A (ja) 2023-06-09
JP2023524274A5 true JP2023524274A5 (https=) 2024-06-14
JP7805010B2 JP7805010B2 (ja) 2026-01-23

Family

ID=78292168

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022566726A Active JP7805010B2 (ja) 2020-05-01 2021-04-29 コロナウイルス感染を予防および処置する化合物および方法

Country Status (7)

Country Link
US (1) US12433901B2 (https=)
EP (1) EP4142713A1 (https=)
JP (1) JP7805010B2 (https=)
CN (1) CN116568295B (https=)
AU (1) AU2021264554A1 (https=)
TW (1) TW202206080A (https=)
WO (1) WO2021222534A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023535714A (ja) * 2020-07-23 2023-08-21 アージル・バイオテック・ホールディング・カンパニー・リミテッド ウイルス感染を阻害するための方法および組成物
US20240408055A1 (en) * 2021-10-21 2024-12-12 Peking University Shenzhen Graduate School Use of anisomelic acid in preparation of pharmaceutical composition for inhibiting infection and replication of sars-cov-2 and variants

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140105928A1 (en) * 2004-01-06 2014-04-17 Paul Edward Stamets Antiviral and antibacterial activity from medicinal mushrooms
CA2481489A1 (en) * 2002-11-29 2004-06-17 Morinaga Milk Industry Co., Ltd. Cysteine protease inhibitor
TWI389699B (zh) * 2009-02-13 2013-03-21 高雄醫學大學 用於誘導細胞凋亡之樟芝子實體乙醇萃取物及其製備方法
US7919665B2 (en) 2009-02-17 2011-04-05 Conocophillips Company Mercury removal from hydrocarbons
TW201231474A (en) * 2011-01-26 2012-08-01 Univ Kaohsiung Medical Triterpenoid composition of Antrodia cinnamomea, preparation and analysis method thereof
FI126047B (en) * 2012-08-28 2016-06-15 John Eriksson Pharmaceutical compositions of anisomelic acid and their use
TWI453026B (zh) * 2013-05-14 2014-09-21 Jenisa Biotechnology Corp Ltd 魚針草萃取物及其純化物抗流感病毒之用途
US9645651B2 (en) 2013-09-24 2017-05-09 Microsoft Technology Licensing, Llc Presentation of a control interface on a touch-enabled device based on a motion or absence thereof
US11253527B2 (en) * 2019-02-25 2022-02-22 Arjil Biotech Holding Company Limited Method and composition for inhibiting virus infection
WO2021202982A1 (en) * 2020-04-03 2021-10-07 Turtle Bear Holdings, Llc Compositions and methods for modulating inflammatory response
CN113521060B (zh) * 2020-04-17 2022-12-06 北京大学深圳研究生院 鱼针草内酯抗新型冠状病毒的用途
TW202200175A (zh) * 2020-04-28 2022-01-01 浩峰生物科技股份有限公司 牛樟芝萃取物(Ant-Ex)減少血管收縮素轉換酶2(ACE-2)蛋白質表現

Similar Documents

Publication Publication Date Title
JP2020023528A5 (https=)
JP2018070614A5 (https=)
JP2024071370A5 (https=)
JP2022515197A5 (https=)
CN111989332A (zh) 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
JP2022081661A5 (https=)
JP2022509091A5 (https=)
JP2020507589A5 (https=)
JP2020500862A5 (https=)
JP2021523112A5 (https=)
JP2024516371A5 (https=)
JP2023524274A5 (https=)
JP2008501705A5 (https=)
JP2023506787A5 (https=)
US20090060874A1 (en) Bicyclic pyrrolidine derivatives
ME00354B (me) Novi lekovi za tretiranje hronićnog opstruktivnog oboljenja pluća
RU2009102278A (ru) Модуляторы рецептора s1p для лечения рассеянного склероза
JP2021152063A5 (https=)
JP2009512659A5 (https=)
JP2022533958A5 (https=)
JP2022552881A5 (https=)
JP2022501327A5 (https=)
JP2022527556A5 (https=)
JP2021534160A5 (https=)
JP2012520321A5 (https=)